Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
17.20
-0.17 (-0.98%)
At close: Nov 28, 2025, 1:00 PM
17.26
+0.06 (0.35%)
After-hours: Nov 28, 2025, 1:42 PM EST
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth. Mesoblast had revenue of $14.04M in the half year ending June 30, 2025, with 244.25% growth.
Revenue (ttm)
$17.20M
Revenue Growth
+191.39%
P/S Ratio
132.37
Revenue / Employee
$212,321
Employees
81
Market Cap
2.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MESO News
- 5 days ago - Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue - GlobeNewsWire
- 9 days ago - Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids - GlobeNewsWire
- 13 days ago - James M. O'Brien Appointed Chief Financial Officer at Mesoblast - GlobeNewsWire
- 25 days ago - Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation - GlobeNewsWire
- 5 weeks ago - Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch - GlobeNewsWire
- 7 weeks ago - Ryoncil® Revenues Increase 66% in Second Quarter Post Launch - GlobeNewsWire
- 7 weeks ago - Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 2 months ago - Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access - GlobeNewsWire